MPDZ

Across TCGA pan-cancer cohorts, MPDZ RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated MPDZ data layer compared with 9 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher MPDZ RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MPDZ expression acts as an unfavorable survival marker, although some lineages such as KIRC and BRCA show a favorable association.

MESO, KIRC, and BRCA are the cancer types where MPDZ RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	III,IV	0.148	0.591	.002	89	view →
KIRC	OS	Median	All	0.703	0.560	<.001	76	view →
BRCA	DFS	Median	III,IV	0.859	0.723	.001	47	view →
LIHC	OS	Quartile	II,III,IV	0.715	0.315	<.001	41	view →
UVM	DFS	Quartile	II,III,IV	0.358	0.842	.007	37	view →
BLCA	DFS	Tertile	All	0.304	0.611	<.001	30	view →
UCS	OS	Tertile	IV	0.844	0.291	.024	24	view →
CESC	DFS	Tertile	All	0.753	0.879	.003	22	view →
LGG	OS	Median	All	0.928	0.859	<.001	21	view →
ESCA	DFS	Median	All	0.926	0.454	.006	21	view →
STAD	OS	Quartile	All	0.480	0.676	.004	19	view →
CHOL	DFS	Median	III,IV	0.127	0.647	.006	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

MPDZ–MESO (DFS)

Open the MESO breakdown →